XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Operating activities    
Net loss $ (32,716) $ (65,035)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 19,372 13,189
Loss on disposal of property and equipment 72 0
Stock-based compensation 19,867 15,787
Benefit from income taxes (270) (5,297)
Interest on end-of-term debt obligation 161 161
Noncash lease expense 2,487 1,566
Revaluation of acquisition-related contingent consideration (80) 303
Effect of foreign currency on operations 1,563 1,601
Impairment of intangible assets 3,318 0
Changes in operating assets and liabilities:    
Accounts receivable (4,356) (6,285)
Supplies and inventory (2,841) 4
Prepaid expenses and other current assets (25) (1,905)
Other assets 160 353
Operating lease liabilities (2,570) (1,710)
Accounts payable (325) 3,872
Accrued liabilities and deferred revenue (6,026) 3,329
Net cash used in operating activities (2,209) (40,067)
Investing activities    
Acquisition of Decipher Biosciences, net of cash acquired 0 (574,411)
Acquisition of HalioDx, net of cash acquired 0 (163,645)
Purchase of short-term investments (8,972) 0
Proceeds from maturity of short-term investments 12,696 0
Proceeds from sale of equity securities 0 3,000
Purchases of property and equipment (6,677) (4,535)
Net cash used in investing activities (2,953) (739,591)
Financing activities    
Proceeds from the issuance of common stock in a public offering, net of issuance costs 0 593,821
Payment of long-term debt (94) 0
Payment of taxes on vested restricted stock units (2,639) (8,307)
Proceeds from the exercise of common stock options and employee stock purchases 6,134 10,633
Net cash provided by financing activities 3,401 596,147
Decrease in cash, cash equivalents and restricted cash (1,761) (183,511)
Effect of foreign currency on cash, cash equivalents and restricted cash (1,324) (1,678)
Net decrease in cash, cash equivalents and restricted cash (3,085) (185,189)
Cash, cash equivalents and restricted cash at beginning of period 173,946 349,967
Cash, cash equivalents and restricted cash at end of period 170,861 164,778
Supplementary cash flow information:    
Purchases of property and equipment included in accounts payable and accrued liability 15 31
Interest paid on debt 0 9
Cash paid for tax 430 0
Issuance of common stock for acquisition of HalioDx 0 147,089
Cash and cash equivalents 170,112  
Restricted cash 749  
Total cash, cash equivalents and restricted cash $ 170,861 $ 164,778